The effect of renal replacement therapies on serum gastrointestinal system hormones

Renal Failure

Volumn 29, Issue 8, 2007, Pages 1019-1023

  Borazan, Ali ^a   Cavdar, Zahide ^b   Saglam, Funda ^b  

^a MUSTAFA KEMAL UNIVERSITY   (Turkey)

^b DOKUZ EYLUL UNIVERSITY   (Turkey)

Author keywords

Amilase; Chronic renal failure; Gastrin; Lipase; Trypsinogen

Indexed keywords

AMYLASE; GASTRIN; GASTROINTESTINAL HORMONE; TRIACYLGLYCEROL LIPASE; TRYPSINOGEN;

ADULT; ARTICLE; CHRONIC KIDNEY FAILURE; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; CONTROLLED STUDY; FEMALE; HEMODIALYSIS; HORMONE BLOOD LEVEL; HORMONE DETERMINATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RENAL REPLACEMENT THERAPY; SEX DIFFERENCE;

ADULT; AMYLASES; CASE-CONTROL STUDIES; FEMALE; GASTROINTESTINAL HORMONES; HUMANS; KIDNEY FAILURE, CHRONIC; LIPASE; MALE; MIDDLE AGED; PERITONEAL DIALYSIS, CONTINUOUS AMBULATORY; RENAL DIALYSIS; TRYPSINOGEN;

EID: 36849064361     PISSN: 0886022X     EISSN: 15256049     Source Type: Journal    
DOI: 10.1080/08860220701643799     Document Type: Article

References (39)

1. Aguilera A, Bajo MA, et al. Gastrointestinal and pancreatic function in peritoneal dialysis patients: Their relationship with malnutrition and peritoneal membrane abnormalities. Am J Kidney Dis. 2003;42:787-796.
2. Kang JY. The gastrointestinal tract in uremia. Dig Dis Sci. 1993;38:257-268.
3. Magnusson M, Magnusson KE, Sundqvist T, Denneberg T. Increased intestinal permeability to differently sized polyethylene glycols in uremic rats: Effects of low- and high-protein diets. Nephron. 1990;56:306-311.
4. Vaziri ND, Dure-Smith B, Miller R, Mirahmadi MK. Pathology of gastrointestinal tract in chronic hemodialysis patients: An autopsy study of 78 cases. Am J Gastroenterol. 1985;80:608-611.
5. Sirinek KR, O'Dorisio TM, Gaskill HV, Levine BA. Chronic renal failure: Effect of hemodialysis on gastrointestinal hormones. Am J Surg. 1984;148:732-735.
6. Suda K, Ariwa R. The islets of Langerhans in uremic patients receiving chronic hemodialysis. Nephron. 1987;46:134-136.
7. Hegbrant J, Thysell H, Ekman R. Plasma levels of gastrointestinal regulatory peptides in patients receiving maintenance hemodialysis. Scand J Gastroenterol. 1991;26:599-604.
8. Katz AI, Emmanouel DS. Metabolism of polypeptide hormones by the normal kidney and in uremia. Nephron. 1978;22:69-80.
9. Honda K, Nitta K, Horita S, Yumura W, Nihei H. Morphological changes in the peritoneal vasculature of patients on CAPD with ultrafiltration failure. Nephron. 1996;72:171-176.
10. Owyang C, Miller LJ, DiMagno EP, Brennan LA, Jr., Go VL. Gastrointestinal hormone profile in renal insufficiency. Mayo Clin Proc. 1979;54:769-773.
11. Owyang C, Miller LJ, DiMagno EP, Mitchell JC, III, Go VL. Pancreatic exocrine function in severe human chronic renal failure. Gut. 1982;23:357-361.
12. Piga M, Altieri P, Floris A, et al. Vasoactive intestinal polypeptide (VIP) plasma levels in chronic renal failure. J Nucl Med Allied Sci. 1984;28:77-80.
13. Malyszko J, Sosnowski S, Mazerska M, et al. Gastric and pancreatic functions in haemodialyzed patients. Int Urol Nephrol. 1995;27:471-478.
14. Aguilera A, Codoceo R, Selgas R, et al. Anorexigen (TNF-alpha, cholecystokinin) and orexigen (neuropeptide Y) plasma levels in peritoneal dialysis (PD) patients: Their relationship with nutritional parameters. Nephrol Dial Transplant. 1998;13:1476-1483.
15. Falcao HA, Wesdorp RI, Fischer JE. Gastrin levels and gastric acid secretion in anephric patients and in patients with chronic and acute renal failure. J Surg Res. 1975;18:107-111.
16. O'Dorisio TM, Sirinek KR, Mazzaferri EL, Cataland S. Renal effects on serum gastric inhibitory polypeptide (GIP). Metabolism. 1977;26:651-656.
17. Ravelli AM. Gastrointestinal function in chronic renal failure. Pediatr Nephrol. 1995;9:756-762.
18. Wright M, Woodrow G, O'Brien S, et al. Cholecystokinin and leptin: Their influence upon the eating behaviour and nutrient intake of dialysis patients. Nephrol Dial Transplant. 2004;19:133-140.
19. Nakahama H, Tanaka Y, Shirai D, et al. Elevated serum pepsinogens in chronic renal failure patients. Nephron. 1995;70:211-216.
20. Sosnowski S, Megraud F, Mitwali A, Rabinovich S, Oreopolos DG. Autopsy findings in patients treated by continuous ambulatory peritoneal dialysis (CAPD). Perit Dial Bull. 1986;6:130-135.
21. Pannekeet MM, Krediet RT, Boeschoten EW, Arisz L. Acute pancreatitis during CAPD in The Netherlands. Nephrol Dial Transplant. 1993;8:1376-1381.
22. Singh S, Wadhwa N. Peritonitis, pancreatitis, and infected pseudocyst in a continuous ambulatory peritoneal dialysis patient. Am J Kidney Dis. 1987;9:84-86.
23. Caruana RJ, Wolfman NT, Karstaedt N, Wilson DJ. Pancreatitis: An important cause of abdominal symptoms in patients on peritoneal dialysis. Am J Kidney Dis. 1986;7:135-140.
24. Masoero G, Bruno M, Gallo L, Colaferro S, Cosseddu D, Vacha GM. Increased serum pancreatic enzymes in uremia: Relation with treatment modality and pancreatic involvement. Pancreas. 1996;13:350-355.
25. Rutsky EA, Robards M, Van Dyke JA, Rostand SG. Acute pancreatitis in patients with end-stage renal disease without transplantation. Arch Intern Med. 1986;146:1741-1745.
26. Gupta A, Yuan ZY, Balaskas EV, Khanna R, Oreopoulos DG. CAPD and pancreatitis: No connection. Perit Dial Int. 1992;12:309-316.
27. Caruana RJ, Burkart J, Segraves D, Smallwood S, Haymore J, Disher B. Serum and peritoneal fluid amylase levels in CAPD. Normal values and clinical usefulness. Am J Nephrol. 1987;7:169-172.
28. Burkart J, Haigler S, Caruana R, Hylander B. Usefulness of peritoneal fluid amylase levels in the differential diagnosis of peritonitis in peritoneal dialysis patients. J Am Soc Nephrol. 1991;1:1186-1190.
29. Kimmel PL, Tenner S, Habwe VQ, Henry J, Lakshminarayan S, Steinberg W. Trypsinogen and other pancreatic enzymes in patients with renal disease: A comparison of high-efficiency hemodialysis and continuous ambulatory peritoneal dialysis. Pancreas. 1995;10:325-330.
30. Lasson A, Borgstrom A, Ohlsson K. Elevated pancreatic secretory trypsin inhibitor levels during severe inflammatory disease, renal insufficiency, and after various surgical procedures. Scand J Gastroenterol. 1986;21:1275-1280.
31. Kaysen GA, Majumdar AP, Dubick MA, Vesenka GD, Mar G, Geokas MC. Biochemical changes in the pancreas of rats with chronic renal failure. Am J Physiol. 1985;249 (4 Pt 2):F518-F523.
32. Geokas MC, Reidelberger R, O'Rourke M, Passaro E Jr, Largman C. Plasma pancreatic trypsinogens in chronic renal failure and after nephrectomy. Am J Physiol. 1982;242:G177-G182.
33. Shepherd AM, Stewart WK, Wormsley KG. Peptic ulceration in chronic renal failure. Lancet. 1973;1:1357-1359.
34. Hallgren R, Landelius J, Fjellstrom KE, Lundqvist G. Gastric acid secretion in uraemia and circulating levels of gastrin, somatostatin, and pancreatic polypeptide. Gut. 1979;20:763-768.
35. Taylor IL, Sells RA, McConnell RB, Dockray GJ. Serum gastrin in patients with chronic renal failure. Gut. 1980;21:1062-1067.
36. Hallgren R, Karlsson FA, Lundqvist G. Serum level of immunoreactive gastrin: Influence of kidney function. Gut. 1978;19:207-213.
37. Gur G, Boyacioglu S, Gul C, et al. Impact of Helicobacter pylori infection on serum gastrin in haemodialysis patients. Nephrol Dial Transplant. 1999;14:2688-2691.
38. Kamata K, Uchida M, Takeuchi Y, et al. Increased serum concentrations of pro-gastrin-releasing peptide in patients with renal dysfunction. Nephrol Dial Transplant. 1996;11:1267-1270.
39. Paimela H, Harkonen M, Karonen SL, Tallgren LG, Ahonen J. The effect of renal transplantation on gastric acid secretion and on the serum levels of gastrin and group I pepsinogens. Ann Clin Res. 1985;17:105-109.